Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,788 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chemotherapy Clear all
Completed Not applicable Interventional

Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians

NCT02502929
View directory record Official record
Conditions
Diabetes, Depression
Interventions
Social Services, Lifestyle, Lifestyle Plus Medication Therapy Management
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
35 Years to 75 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Farmington, Connecticut • West Hartford, Connecticut • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Apixaban, No systemic anticoagulant prophylaxis
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 3 Interventional

Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

NCT00006453
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, gemcitabine hydrochloride
Drug
Lead sponsor
AGO Study Group
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma

NCT01259375
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Amrubicin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Santa Monica, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

NCT04172675
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

NCT00002357
View directory record Official record
Conditions
HIV Infections
Interventions
HBY 097, Zidovudine
Drug
Lead sponsor
Hoechst Marion Roussel
Industry
Eligibility
13 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00869401
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
dasatinib, temozolomide, placebo, radiation therapy
Drug · Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
207
States / cities
Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Not applicable Interventional

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

NCT00129792
View directory record Official record
Conditions
Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions
Dietary supplement for weight loss, Education and counseling for weight loss
Drug · Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 60 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 2 Interventional

High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

NCT00003392
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
14
States / cities
La Jolla, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 3 Interventional

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

NCT00002836
View directory record Official record
Conditions
Breast Cancer
Interventions
Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 1 Interventional

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

NCT00004580
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Beverly Hills, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Not applicable Interventional Results available

Tango for Neuropathy Among Breast Cancer Survivors

NCT05114005
View directory record Official record
Conditions
Cancer, Breast, Neuropathy
Interventions
Rhythmic Auditory Stimulation, Evidence-Based Exercise
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

NCT02996565
View directory record Official record
Conditions
Hypertension
Interventions
Best Practice Clinic-Based Care, Telehealth Care
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
3,071 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas

NCT00766467
View directory record Official record
Conditions
Malignant Glioma
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Eudocia Quant Lee, MD
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
La Jolla, California • Boston, Massachusetts • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

NCT00995007
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions
ZD6474 (Vandetanib), Carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 2 Interventional Results available

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

NCT02756364
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Fulvestrant, Sapanisertib
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Bakersfield, California • Fullerton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 20, 2026, 8:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Enfortumab vedotin, Pembrolizumab, Cisplatin, Carboplatin, Gemcitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Tucson, Arizona • Burbank, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 8:50 PM EDT
Recruiting No phase listed Observational

Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT04616131
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
3
States / cities
DeKalb, Illinois • Geneva, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 20, 2026, 8:50 PM EDT
Not listed Phase 3 Interventional

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005002
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate
Drug · Biological
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Not applicable Interventional Results available

Wearable Focal Vibration for Chemotherapy-Induced Peripheral Neuropathy

NCT04959929
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Focal vibration therapy
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

NCT02041429
View directory record Official record
Conditions
Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions
Ruxolitinib, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 1 Interventional

Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation

NCT00768729
View directory record Official record
Conditions
Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions
Sirolimus, MMF or Azathioprine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Madera, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 20, 2026, 8:50 PM EDT
Completed No phase listed Observational

Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial

NCT00924131
View directory record Official record
Conditions
Hodgkin's Disease, Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 8:50 PM EDT
Completed Phase 3 Interventional Results available

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00004031
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, carmustine, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 65 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 20, 2026, 8:50 PM EDT